TPTX Turning Point Therapeutics Inc.

FDA Catalyst Company
35.67
+3.19  (+10%)
Previous Close 32.48
Open 33.5
52 Week Low 23.77
52 Week High 83.06
Market Cap $1,771,596,493
Shares 49,666,288
Float 47,191,233
Enterprise Value $643,117,988
Volume 195,585
Av. Daily Volume 696,071
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/11/2022
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/22/2022
Stifel Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/01/2022
Wells Fargo Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/10/2022
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/21/2022
Cowen & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/07/2021
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/10/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/12/2021
JMP Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/11/2021
Stifel Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 09/30/2021

Latest News

  1. SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022.

    Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members. In this role he provided executive leadership to scale the company's $3 billion U.S. oncology franchise by launching and growing new products. His achievements include successfully expanding the market for Xtandi®, directing…

    View Full Article
    • Granted Third Breakthrough Therapy Designation (BTD) for Repotrectinib for the treatment of patients with ROS1-positive Metastatic NSCLC who have been Previously Treated with One ROS1 TKI and who have not Received Prior Platinum-Based Chemotherapy
    • Reported Positive Topline Data by BICR for Repotrectinib in ROS1+ NSCLC from Phase 1/2 TRIDENT-1 Study and Remain On-Track for Pre-NDA Meeting Anticipated Later This Quarter
    • Completed Enrollment into the Intermediate Dose Level Cohort for Elzovantinib in SHIELD-1 Study and Anticipate Initiating Phase 2 in the Second Half of 2022 Pending FDA Feedback
    • Announced Clinical Pipeline Expansion with the Exclusive In-License of TPX-4589 (LM-302), a Clinical-Stage Claudin18.2 Antibody Drug Conjugate for Gastrointestinal
    View Full Article
  2. SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Administration (FDA) granted an eighth regulatory designation, and third Breakthrough Therapy designation, to lead drug candidate repotrectinib.

    Breakthrough Therapy designation (BTD) was granted for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with one ROS1 tyrosine kinase inhibitor and who have not received prior platinum-based chemotherapy. The efficacy analyses supporting the BTD application included approximately…

    View Full Article
  3. Strategic Expansion of Turning Point Precision Oncology Portfolio

    TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies

    Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs

    SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater China and South Korea. Claudin18.2 is a protein expressed…

    View Full Article
    • 91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1)
    • In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+ months with median DOR follow-up of 3.7 months

    • 36-67% cORR by BICR in China subpopulation across three TKI-pretreated cohorts (EXP-2, EXP-3, and EXP-4)

    • Zai Lab plans to discuss topline TKI-naïve data with Chinese health authority in the fourth quarter of 2022

    SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ:ZLAB, HKEX: 9688))), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Turning Point Therapeutics…

    View Full Article
View All Turning Point Therapeutics Inc. News